Shares of Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) have been given an average rating of “Hold” by the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.00.
A number of research firms have commented on MDCX. Roth Capital assumed coverage on Medicus Pharma in a research report on Tuesday, April 21st. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Alliance Global Partners began coverage on Medicus Pharma in a research note on Tuesday. They issued a “buy” rating on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th.
Get Our Latest Stock Analysis on Medicus Pharma
Medicus Pharma Price Performance
Medicus Pharma (NASDAQ:MDCX – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, equities analysts predict that Medicus Pharma will post -0.51 EPS for the current fiscal year.
Institutional Investors Weigh In On Medicus Pharma
A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Medicus Pharma during the 2nd quarter worth approximately $41,000. HRT Financial LP purchased a new position in shares of Medicus Pharma in the 4th quarter worth approximately $42,000. Osaic Holdings Inc. grew its stake in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares during the period. Commonwealth Equity Services LLC grew its position in Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after buying an additional 17,611 shares during the period. Finally, May Hill Capital LLC grew its holdings in Medicus Pharma by 100.0% during the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after purchasing an additional 17,811 shares during the period.
Medicus Pharma Company Profile
Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.
Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.
Featured Stories
- Five stocks we like better than Medicus Pharma
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
- 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
- Middleby Is Betting a Leaner Business Can Unlock More Value
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
